Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)* of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Science, Space and Technology
Subcommittee:
Hearing Date: 04/15/2021
Hearing Title :
Reimagining our Innovation Future
Witness Name: Frances H. Arnold
Position/Title: Linus Paul Professor of Chemical Engineering, Bioengineering and Biochemistry, California Institute of Technology
Witness Type: ○ Governmental • Non-governmental
Are you representing yourself or an organization? Self Organization
If you are representing an organization, please list what entity or entities you are representing:
FOR WITNESSES APPEARING IN A NON-GOVERNMENTAL CAPACITY
Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.
Are you a fiduciary—including, but not limited to, a director, officer, advisor, or resident agent—of any organization or entity that has an interest in the subject matter of the hearing? If so, please list the name of the organization(s) or entities.
Alphabet (Director) Illumina (Director) Provivi (co-founder and Director) Generate Biomedicines (Director) National Resilience (Director) Aralez Bio (co-founder) Entos AI (science advisor) Twist Biociences (science advisor) Catalio Capital Management LP (advisor)

Please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you, the organization(s) you represent, or entities for which you serve as a fiduciary have received in the past thirty-six months from the date of the hearing. Include the source and amount of each grant or contract.
See attached list.
Please list any contracts, grants, or payments originating with a foreign government and related to the hearing's subject that you, the organization(s) you represent, or entities for which you serve as a fiduciary have received in the past thirty-six months from the date of the hearing. Include the amount and country of origin of each contract or payment.
Tianjin Institute of Biotechnology, China in December, 2019. Participated in science advisory board meeting, \$22,000 compensation.
Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.
☑ I have attached a written statement of proposed testimony.
☑ I have attached my curriculum vitae or biography.

- (5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.
- (B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include—
 (i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing.
- (C) The disclosure referred to in subdivision (B)(iii) shall include—(i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.
- (D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

^{*} Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides: